By Tort Law Team 
Genetic testing now shapes how clinicians manage chronic disease, yet many practices still struggle to find reliable partners for next-generation sequencing and molecular diagnostics. Tesis Labs LLC entered this space with a genetically integrated platform aimed at physicians, hospitals, and researchers. This guide examines the company’s background, service offerings, laboratory footprint, corporate evolution, and diagnostic capabilities so healthcare providers, geneticists, billing teams, and investors can evaluate it against real-world needs.
Company Background and Corporate Evolution
Tesis Labs LLC formed in 2019 as a Delaware limited liability company. Early filings listed a Phoenix, Arizona address on East Camelback Road. The firm positioned itself as a provider of targeted genetic sequencing and precision-medicine tools that help clinicians build personalized care plans for chronic conditions such as heart disease, lung disease, cancer, diabetes, and Alzheimer’s.
In November 2021 the company announced a formal name change to Tesis Biosciences. Leadership described the shift as a reflection of broader ambitions that extended beyond routine lab services into collaborative clinical research and diagnostic partnerships with medical-device and pharmaceutical firms. Public statements at the time emphasized support for hospitals, health systems, value-based care organizations, and research groups seeking next-generation sequencing results that improve population-health outcomes.
Funding milestones included approximately $15 million raised internally before a $20 million growth-equity round in October 2021 led by an investment group associated with John Shufeldt, M.D. The round valued the company at a post-money figure of $520 million and supported capacity expansion. Later profiles listed total capital raised in the range of $35 million to $40 million. In early 2022 Tesis Biosciences acquired Genome Explorations, a Memphis-based genomic-profiling and molecular-diagnostics provider, to accelerate proprietary product development.
Operational laboratories operated under related entities. Tesis Labs LLC owned and managed Claro Scientific Laboratories in Lafayette, Colorado, 303 Diagnostics LLC (initially in Denver, later relocated to Aurora), and Alliance DX LLC in Texas. These sites formed the core testing network. A Scottsdale, Arizona facility opened to serve western U.S. demand and house high-complexity molecular and next-generation sequencing work.
In September 2024 a federal grand jury in Colorado indicted seven individuals, including Ronald King (listed as CEO of Tesis Labs LLC), on charges related to an alleged scheme to defraud Medicare and Colorado Medicaid of more than $40 million. Prosecutors alleged medically unnecessary genetic testing, kickbacks, and related conduct involving the Colorado laboratories. The indictment remains a matter of public record; readers should consult primary court documents for the latest procedural status. PitchBook later recorded Tesis Biosciences as out of business effective December 2025, though related laboratory entities and a web presence continued to list service locations.
These developments illustrate both rapid growth in the specialized-diagnostics sector and the compliance risks that accompany high-volume genetic testing reimbursement. Healthcare managers evaluating any laboratory partner should verify current CLIA status, payer enrollment, and ownership structure independently.
Core Service Offerings and Diagnostic Capabilities
Tesis Labs LLC and its successor focused on high-complexity clinical laboratory testing. The platform combined targeted genetic sequencing, bioinformatic testing, and result reporting designed for integration into physician workflows. Key categories included pharmacogenomic screening, hereditary cancer and mutation panels, pulmonary and cardiac testing, and supporting molecular assays.
Pharmacogenomic Screening
Pharmacogenomics (often abbreviated PGx) formed a central offering. The company developed assays intended to predict how a patient’s genetic makeup affects drug metabolism, efficacy, and risk of adverse reactions. One announced panel claimed coverage of thousands of drugs across dozens of therapeutic classes, including agents used for cancer, depression, diabetes, hypertension, and chronic pain. The test drew on proprietary bioinformatics that consolidated public databases and peer-reviewed literature. Results aimed to guide dosage and selection decisions, potentially reducing trial-and-error prescribing.
A later iteration targeted a comprehensive, once-and-done format suitable for both clinical and possible direct-to-consumer channels. It examined single-nucleotide polymorphisms, indels, and copy-number variation on a Thermo Fisher platform. Turnaround times were described as approximately three days from cheek-swab collection. Leadership indicated plans to seek FDA marketing authorization after initial laboratory-developed-test use and reported that the underlying assay had received CLIA certification.
Practical applications included fall-prevention protocols in senior-care settings and medication optimization for accountable-care organizations. Partnerships with senior-living operators and ACOs positioned PGx as a tool for both clinical quality and cost management.
Hereditary Cancer Screening and Targeted DNA Testing
Hereditary cancer screening and related targeted DNA testing panels addressed somatic and germline variants linked to cancer predisposition and treatment response. Collaboration announcements highlighted work with Personal Genome Diagnostics on cancer profiling. Services supported oncologists seeking biomarkers that inform therapy selection. Complementary panels covered carrier testing, neonatal conditions, and other hereditary risks.
The company also listed specialty panels for pulmonary disease (rare lung conditions), cardiac risk, diabetes and obesity (including MODY and neonatal diabetes panels), neurology, urology, wound care, and anesthesia-related genetic factors. Cytology and pathology services rounded out the menu in some location descriptions.
Next-Generation Sequencing and Molecular Diagnostics Infrastructure
Next-generation sequencing formed the technical backbone. Laboratories performed high-complexity molecular testing with emphasis on rapid turnaround, HL7 or API interfacing, and real-time result portals. Marketing materials stressed 24/7 access to laboratory experts, patient-first processes, and accredited laboratory operations. Infectious-disease testing, including respiratory and wound panels, appeared in earlier expansion announcements.
Bioinformatic pipelines converted raw sequencing data into clinician-friendly reports. The goal was to deliver actionable insights rather than raw variant lists, supporting precision-medicine plans that span individual patients and family members.
Laboratory Locations and Operational Footprint
Geographic coverage centered on three primary sites:
- Scottsdale / Phoenix area, Arizona (8125 N 86th Place, Scottsdale), described as the largest capacity facility and western hub.
- Aurora, Colorado (2953 S. Peoria Street, Suite 260), successor to earlier Denver and Lafayette operations.
- Houston, Texas (16115 Park Row, Suite 190).
These locations supported physicians, physician groups, and hospitals seeking complex clinical diagnostic testing. Earlier sites in Lafayette and Denver fed into the Colorado footprint after acquisitions. Joint-venture discussions with ACOs contemplated possible on-site or near-site laboratory presence in additional states such as Georgia.
Operational claims included consistently fast turnaround, quality diagnostics as the top priority, and payer communication handled with attention to patient interest. Billing and administrative teams should confirm current enrollment status with Medicare, Medicaid, and commercial payers, especially given the public record of the 2024 indictment.
Partnerships and Industry Collaborations
Tesis Labs LLC pursued collaborative models. Notable agreements included:
- Premier Health ACO (Georgia and Kentucky practices) for cardiac, pulmonary, neonatal, carrier, and pharmacogenomic testing.
- Pathways Health Partners ACO in Florida for NGS and precision-medicine services.
- Frontier Management senior-living facilities for exclusive PGx services within pharmacy-management programs.
- Personal Genome Diagnostics for cancer-genomics collaboration.
- Acquisition of Genome Explorations to integrate research data and accelerate product pipelines.
These relationships illustrate a strategy of embedding genetic testing inside value-based and population-health frameworks rather than relying solely on fee-for-service volume. Device and pharmaceutical partners were invited to use the platform for clinical-trial support and diagnostic-outcome improvement.
Regulatory and Quality Considerations
Clinical laboratories performing high-complexity testing must maintain CLIA certification. Public statements from Tesis Biosciences referenced CLIA certification for its pharmacogenomics assay. Readers should verify current certificates through the Centers for Medicare & Medicaid Services database or state agencies, as status can change. Accreditation claims on company materials should likewise be confirmed independently.
Payer policy remains a practical constraint. Coverage for pharmacogenomics and broad hereditary panels varies by plan and medical-necessity documentation. Medical-office billing personnel need clear coding guidance and medical-necessity criteria before ordering. Unnecessary or inadequately documented testing can trigger audits, as the 2024 federal case demonstrates.
From a compliance standpoint, any laboratory relationship requires due diligence on ownership, referral relationships, and marketing practices. Anti-kickback and Stark considerations apply when marketing companies or referral sources receive compensation.
Practical Evaluation for Healthcare Providers
When assessing Tesis Labs LLC or any successor entity, consider the following checklist:
- Confirm active CLIA certificate numbers and laboratory directors for each testing site.
- Review current test menu against clinical needs (PGx, CGx, specialty panels).
- Evaluate interface options (HL7, API, portal) for electronic health-record integration.
- Assess turnaround-time performance data and quality metrics if available.
- Examine payer contracts and prior-authorization requirements.
- Document medical necessity thoroughly for every order.
- Monitor public records for ongoing litigation or ownership changes.
Patients and investors benefit from the same transparency. Genetic results can influence family counseling, lifestyle decisions, and long-term care planning; accurate, timely reporting therefore carries clinical weight beyond the individual test.
Conclusion
Tesis Labs LLC built a platform centered on genetic sequencing, molecular diagnostics, and pharmacogenomics to support precision care for chronic disease. Its laboratories in Arizona, Colorado, and Texas, combined with ACO and research partnerships, positioned the company as a specialized option for clinicians seeking targeted DNA testing and hereditary cancer screening. Corporate evolution into Tesis Biosciences expanded the stated mission into collaborative research, yet public records of a major fraud indictment and subsequent business-status reports introduce material uncertainty. Healthcare professionals should treat the company overview as historical and operational context, verify every credential and contract in real time, and prioritize laboratories that demonstrate sustained regulatory compliance and transparent result quality. For current ordering decisions, contact the laboratory directly, review CMS certification data, and consult institutional compliance counsel.
Frequently Asked Questions
What is Tesis Labs LLC and how does it relate to Tesis Biosciences?
Tesis Labs LLC was the original legal entity formed around 2019. In 2021 it rebranded as Tesis Biosciences to reflect an expanded focus on clinical research and diagnostics. Public materials continue to reference both names in connection with the same laboratory network.
Does Tesis Labs offer CLIA-certified testing?
Company announcements stated that its pharmacogenomics assay held CLIA certification. Independent verification through CMS or state laboratory directories remains essential for any current orders.
What types of genetic tests does the laboratory perform?
Offerings have included pharmacogenomic panels, hereditary cancer and mutation (CGx) testing, pulmonary and cardiac panels, diabetes-related sequencing, carrier and neonatal testing, and other molecular diagnostics supported by next-generation sequencing.
Where are the main laboratory locations?
Documented sites include Scottsdale, Arizona; Aurora, Colorado; and Houston, Texas. Earlier operations existed in Lafayette and Denver, Colorado.
How does pharmacogenomic testing from this company work?
A cheek-swab or other specimen is analyzed for genetic variants that influence drug metabolism. Proprietary bioinformatics generate reports intended to guide medication selection and dosing across multiple therapeutic classes.
What should clinics know about billing and compliance?
Medical necessity documentation is critical. The 2024 federal indictment involving company executives underscores the importance of verifying that ordered tests meet coverage criteria and that referral arrangements comply with federal law.
Is the company still operating?
Public sources present mixed signals. A web presence lists active locations and services, while commercial databases have recorded an out-of-business status. Prospective users must confirm operational status, ownership, and certification directly before relying on any laboratory.